Accidental extravasation of anthracycline-containing anticancer chemotherapy is a feared complication that may lead to progressive tissue damage. The condition may require extensive surgical intervention and often has severe long-term effects. Until a short while ago, there has been no effective treatment against the devastating effect of extravasated anthracycline. However, dexrazoxane has proven highly effective in preventing necrosis in both preclinical and clinical studies and is now approved in Europe (Savenetrade mark), and has orphan drug status in the USA (Totecttrade mark) for this indication. Hence, it is the first and only proven effective antidote against anthracycline extravasation injuries.
Dexrazoxane for anthracycline extravasation. Publishing Authors By Initials
Dexrazoxane for anthracycline extravasation. Journal Published:
PUBLICATION TYPE: Journal Article
Journal: Expert review of anticancer therapy
VOLUME: 7
Page Numbers: 1081-8
Journal Abbreviation: Expert Rev Anticancer Ther
ISSN: 1744-8328
DAY: 21
MONTH: Aug
YEAR: 2007
Dexrazoxane for anthracycline extravasation. Information
Number of References:
LANGUAGE: eng
NlmUniqueID: 101123358
Dexrazoxane for anthracycline extravasation. Keywords Mesh Terms:
KEYWORDS:
MESH TERMS:
Chemical & Substance for Abstract: Dexrazoxane for anthracycline extravasation. Information
Substance Name:
Registry Number:
Grant and Affiliation Information for Dexrazoxane for anthracycline extravasation.
AFFILIATION: Chief Medical Oncologist, Copenhagen University Hospital, Rigshospitalet, Department of Oncology, Section 5073, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. seppo.langer@rh.regionh.dk.
Country: England
AGENCY:
GRANT:
ACRONYM:
MEDLINETA: Expert Rev Anticancer Ther
REFSOURCE:
DATABASENAME:
ACCESSION NUMBER:
Number Hits: 0
Dexrazoxane for anthracycline extravasation Related Publications